Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379472 | 1.00 | CA12 (0.74) | CA12RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL4896484 | 0.90 | CA12 (0.84) | CA12RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL4896487 | 0.90 | CA12 (0.84) | CA12RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL14163515 | 0.90 | CA12 (0.84) | CA12RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL11966962 | 0.84 | CA12 (0.74) | CA12RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL22013355 | 0.81 | CA12 (0.80) | CA12RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL9112821 | 0.78 | CA12 (0.65) | CA12RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL9112827 | 0.78 | CA12 (0.65) | CA12RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL29035946 | 0.78 | CA12 (0.60) | CA12RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL700769 | 0.74 | CA12 (0.60) | CA12RAB9AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242264-B2 | Process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2012-08-14 | — | — | US | disclosed |
| US-8242264-B2 | Process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2012-08-14 | — | — | US | disclosed |
| US-8242264-B2 | Process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2012-08-14 | — | — | US | disclosed |
| EP-2163538-B1 | PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES | TOPHARMAN SHANGHAI CO LTD (CN) | 2012-01-25 | — | — | EP | disclosed |
| EP-2163538-B1 | PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES | TOPHARMAN SHANGHAI CO LTD (CN) | 2012-01-25 | — | — | EP | disclosed |
| US-20100256358-A1 | Process for Preparing 4-Acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the Intermediates Thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2010-10-07 | — | — | US | disclosed |
| US-20100256358-A1 | Process for Preparing 4-Acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the Intermediates Thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2010-10-07 | — | — | US | disclosed |
| US-20100256358-A1 | Process for Preparing 4-Acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the Intermediates Thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2010-10-07 | — | — | US | disclosed |
| EP-2163538-A1 | PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES | Topharman Shanghai Co., Ltd. (CN) | 2010-03-17 | — | — | EP | disclosed |
| EP-2163538-A1 | PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES | Topharman Shanghai Co., Ltd. (CN) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256358-A1 | Process for Preparing 4-Acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the Intermediates Thereof | NQO1, KAT2A, HDAC2 | CA12 865/4885RAB9A 2147/4885MEN1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.